Aging | GrimAge version 2 DNA methylation

Figure 1

image: Figure 1. GrimAge2 mDNA.
view plus

Credit: 2022 Lu et al.

“[…] GrimAge2 complements existing clinical biomarkers by assessing the rate of aging of an individual.”

BUFFALO, NY- December 21, 2022 – A new research paper was published in Aging (listed as “Aging (Albany NY)” by MEDLINE/PubMed and “Aging-US” by Web of Science) Volume 14, Number 23with right, “GrimAge version 2 DNA methylation.”

researchers Ake T. Lu, Alexandra M. Binder, Joshua Zhang, Qi Yan, Alex P. Reiner, Simon R. Cox, Janie Corley, Sarah E. Harris, Pei-Lun Kuo, Ann Z. Moore, Stefania Bandinelli, James D. Stewart, Cuicui Wang, Elissa J. Hamlat, Elissa S. Epel, Joel D. Schwartz, Eric A. Whitsel, Adolfo Correa, Luigi Ferrucci, Riccardo E. Marioni, Y steve horvath from the University of California, Los Angeles, high labs, University of Hawaii at Manoa, Fred Hutchinson Cancer Research Center, University of Edinburgh, National Institute on Aging, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Harvard T.H. Chan School of Public Health, University of California – San Franciscoand the University of Mississippi Medical Center previously described a DNA methylation (mDNA)-based biomarker of human mortality risk DNAmGrimAge. In their current study, the researchers describe version 2 of GrimAge (trained in people aged 40-92) that leverages two new mDNA-based estimators of plasma proteins (log transformed): high-sensitivity C-reactive protein (logCRP). ) and hemoglobin A1C ( logA1C).

“To get to version 2 of GrimAge, we developed two additional mDNA-based surrogates for plasma proteins that are widely used in the clinic (mDNA logCRP and mDNA logA1C).”

The team tested GrimAge2 in 13,399 blood samples in nine study cohorts. After adjustment for age and sex, GrimAge2 outperforms GrimAge in predicting mortality across multiple racial/ethnic groups (meta P=3.6×10-167 vs. P=2.6×10-144) and in terms of associations with related conditions with age, such as coronary heart disease, FEV1 lung function measurement (correlation = -0.31, P = 1.1×10-136), CT-based measurements of fatty liver disease. The researchers presented evidence that GrimAge version 2 also applies to younger individuals and to saliva samples where it tracks markers of metabolic syndrome.

mDNA logCRP is positively correlated with morbidity count (P = 1.3×10-54). mDNA logA1C is highly associated with type 2 diabetes (P = 5.8×10-155). PAI-1 mDNA outperforms other age-adjusted mDNA biomarkers, including GrimAge2, in correlation with triglycerides (cor=0.34, P=9.6×10-267) and visceral fat (cor=0.41, P=4.7×10-41). Overall, the team demonstrated that GrimAge version 2 is an attractive epigenetic biomarker of human mortality and morbidity risk.

“GrimAge2 will not replace existing clinical biomarkers. Rather, GrimAge2 complements existing clinical biomarkers by assessing an individual’s rate of aging.”


Corresponding author: steve horvath

Corresponding email:

Keywords: DNA methylation, epigenetic clock, mortality, health

Sign up for free alerts from Altmetric on this item:

On Aging-USA USA:

Released in 2009, Aging (Aging-US) publishes articles of general interest and biological significance in all fields of research on aging and age-related diseases, including cancer, and now, with a special focus on the vulnerability of COVID-19 as an age-dependent syndrome. age. Topics in Aging going beyond traditional gerontology, including, but not limited to, cell and molecular biology, human age-related diseases, pathology in model organisms, signal transduction pathways (eg, p53, sirtuins, and PI-3K/AKT /mTOR, among others) and approaches to modulate these signaling pathways.

Please visit our website at www.aging-us.comand connect with us:

For media inquiries, please contact

Aging (Aging-US) Journal Office

6666 E. Quaker Str., Suite 1B

Orchard Park, New York 14127

Phone: 1-800-922-0957, option 1


Disclaimer: AAAS and Eurek Alert! are not responsible for the accuracy of the press releases published on EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.

Leave a Reply

Your email address will not be published. Required fields are marked *